When to get a flu shot: See what new option is available
Flu season in the U.S. is expected to peak from December to February. The CDC recommends trivalent flu vaccines covering Influenza A H1N1, H3N2, and Influenza B. Moderna's mRNA flu vaccine, mFLUSIVA, is approved for adults 50+; side effects include fatigue and injection site pain. The CDC advises certain groups, like children under 6 months, to avoid flu vaccines.
How this was made
The 30-second read
Why it matters
The approval adds a novel product to Moderna's portfolio, potentially increasing sales and investor interest.
Market read
First FDA approval of an mRNA flu vaccine could drive biotech sector momentum and affect Moderna's stock.
What to watch
Reimbursement rates and competition from existing flu vaccines may limit revenue.
Background
The article outlines flu season expectations and introduces Moderna's newly approved mRNA flu vaccine.
Ticker impact
FDA approved Moderna's new mRNA flu vaccine (mFLUSIVA) for adults 50+, a first-of-its-kind product.
upward pressure as investors price in potential revenue from the novel flu vaccine
FDA approval of a new vaccine expands Moderna's product pipeline and opens a sizable seasonal market.
Market effects
Boosts biotech and vaccine sector sentiment, may lift peers with similar pipelines.
U.S. market may see modest gains in healthcare stocks.
Limited to markets tracking biotech developments.
Counterpoint
If the vaccine faces distribution or efficacy concerns, the upside could be muted.
Key entities
- CompanyModerna
Biotech firm that received FDA approval for a new mRNA flu vaccine.
- Regulatory AgencyFDA
U.S. Food and Drug Administration that approved the vaccine.
